# Camurus

Source: https://onco.cc/companies/camurus/  
OnCo record `camurus` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Camurus is a Swedish drug-delivery company whose FluidCrystal depot turns injections into long-acting formulations; CAM2029 is its monthly octreotide depot for acromegaly and neuroendocrine tumours.

## Summary

Camurus develops long-acting medicines built on its FluidCrystal lipid-based depot technology, which forms a slow-release gel after subcutaneous injection. Its marketed products include Buvidal for opioid dependence. In oncology and endocrinology it is developing CAM2029 (octreotide subcutaneous depot, branded Oczyesa in some markets) for acromegaly, gastroenteropancreatic neuroendocrine tumours and polycystic liver disease, and in-licensed rights to a long-acting treprostinil.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: Camurus AB; STO:CAMX
- Tags: drug-maker
- HQ: Lund
- Type: pharma
- Website: https://www.camurus.com/
- Ticker: STO:CAMX

## Sources

- Official website: https://www.camurus.com/

## Connected records

- drugs: [CAM2029 (octreotide subcutaneous depot)](https://onco.cc/drugs/cam2029/)

---
JSON: https://onco.cc/api/v1/entities/camurus.json